Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Nov 18, 2024

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Nov 13, 2024

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Oct 21, 2024

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Oct 17, 2024

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Oct 16, 2024

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Sep 26, 2024

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Sep 24, 2024

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

Aug 9, 2024

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Jul 17, 2024